Head and Neck Diseases by Alexandros G.Sfakianakis: Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).

Σάββατο 31 Μαρτίου 2018

Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).

https:--linkinghub.elsevier.com-ihub-ima

Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).

Ophthalmology. 2017 01;124(1):e5

Authors: Shanmugam MP, Harshey KB, Ramanjulu R, Mishra DK

PMID: 27993278 [PubMed - indexed for MEDLINE]

https://ift.tt/2IitpQs

Head and Neck Diseases by Alexandros G.Sfakianakis

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Σάββατο 31 Μαρτίου 2018

Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359).

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου